These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 15186595

  • 1. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats.
    Brouwers A, Verel I, Van Eerd J, Visser G, Steffens M, Oosterwijk E, Corstens F, Oyen W, Van Dongen G, Boerman O.
    Cancer Biother Radiopharm; 2004 Apr; 19(2):155-63. PubMed ID: 15186595
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
    Brouwers A, Mulders P, Oosterwijk E, Buijs W, Corstens F, Boerman O, Oyen W.
    Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961
    [Abstract] [Full Text] [Related]

  • 3. ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.
    Stillebroer AB, Franssen GM, Mulders PF, Oyen WJ, van Dongen GA, Laverman P, Oosterwijk E, Boerman OC.
    Cancer Biother Radiopharm; 2013 Sep; 28(7):510-5. PubMed ID: 23697926
    [Abstract] [Full Text] [Related]

  • 4. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
    Lawrentschuk N, Lee FT, Jones G, Rigopoulos A, Mountain A, O'Keefe G, Papenfuss AT, Bolton DM, Davis ID, Scott AM.
    Urol Oncol; 2011 Sep; 29(4):411-20. PubMed ID: 19523858
    [Abstract] [Full Text] [Related]

  • 5. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC.
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [Abstract] [Full Text] [Related]

  • 6. 131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study.
    Brouwers AH, Dorr U, Lang O, Boerman OC, Oyen WJ, Steffens MG, Oosterwijk E, Mergenthaler HG, Bihl H, Corstens FH.
    Nucl Med Commun; 2002 Mar; 23(3):229-36. PubMed ID: 11891480
    [Abstract] [Full Text] [Related]

  • 7. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.
    Cheal SM, Punzalan B, Doran MG, Evans MJ, Osborne JR, Lewis JS, Zanzonico P, Larson SM.
    Eur J Nucl Med Mol Imaging; 2014 May; 41(5):985-94. PubMed ID: 24604591
    [Abstract] [Full Text] [Related]

  • 8. In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations.
    Steffens MG, Oosterwijk E, Kranenborg MH, Manders JM, Debruyne FM, Corstens FH, Boerman OC.
    J Nucl Med; 1999 May; 40(5):829-36. PubMed ID: 10319758
    [Abstract] [Full Text] [Related]

  • 9. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
    Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA.
    J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250.
    Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, Koenders EB, Oyen WJ, Buijs WC, Debruyne FM, Corstens FH, Oosterwijk E.
    J Clin Oncol; 1997 Apr; 15(4):1529-37. PubMed ID: 9193349
    [Abstract] [Full Text] [Related]

  • 12. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
    Hoeben BA, Kaanders JH, Franssen GM, Troost EG, Rijken PF, Oosterwijk E, van Dongen GA, Oyen WJ, Boerman OC, Bussink J.
    J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
    [Abstract] [Full Text] [Related]

  • 13. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.
    Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, Brouwers AH, van Dongen GA, Perk LR, Lub-de Hooge MN.
    J Nucl Med; 2007 Aug; 48(8):1313-9. PubMed ID: 17631557
    [Abstract] [Full Text] [Related]

  • 14. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
    Börjesson PK, Jauw YW, de Bree R, Roos JC, Castelijns JA, Leemans CR, van Dongen GA, Boellaard R.
    J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Immuno-PET of human colon xenograft- bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody.
    Lee FT, Hall C, Rigopoulos A, Zweit J, Pathmaraj K, O'Keefe GJ, Smyth FE, Welt S, Old LJ, Scott AM.
    J Nucl Med; 2001 May; 42(5):764-9. PubMed ID: 11337573
    [Abstract] [Full Text] [Related]

  • 17. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy.
    Steffens MG, Boerman OC, Oyen WJ, Kniest PH, Witjes JA, Oosterhof GO, van Leenders GJ, Debruyne FM, Corstens FH, Oosterwijk E.
    Cancer Res; 1999 Apr 01; 59(7):1615-9. PubMed ID: 10197637
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.